Clene Inc. to Showcase Corporate Progress at Emerging Growth Conference

Clene Inc. (NASDAQ: CLNN), a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for neurodegenerative diseases such as ALS and MS, is scheduled to present a corporate update at the Emerging Growth Conference on August 20, 2025. The presentation, slated for 2:20 p.m. ET, will be conducted virtually, offering stakeholders and interested parties a comprehensive overview of the company's latest developments and strategic direction. Following the update, attendees will have the opportunity to engage with Clene's leadership during a Q&A session.

The event will be accessible via a live webcast, available through the Events section of Clene’s website or via the conference registration link. For those unable to attend live, replays will be made available through the conference portal and on YouTube, ensuring broad access to the information presented. This presentation is a significant opportunity for investors and the medical community to gain insights into Clene's progress and future plans, particularly regarding its investigational therapy, CNM-Au8(R), which aims to improve mitochondrial health and neuronal function in patients with neurodegenerative diseases.

Clene's focus on neurodegenerative diseases addresses a critical unmet medical need, with potential implications for millions of patients worldwide. The company's innovative approach, targeting mitochondrial function and the NAD pathway, represents a promising avenue for the development of effective treatments. The upcoming presentation at the Emerging Growth Conference is a testament to Clene's commitment to transparency and engagement with its stakeholders, as it continues to advance its research and development efforts. For more information on Clene Inc. and its groundbreaking work, visit https://www.clene.com.